The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 12, 2004, Pages 1355-1363

  Walldus, Göran ^a,b   Jungner, Ingmar ^a,c   Aastveit, Are H ^d   Holme, Ingar ^e   Furberg, Curt D ^f   Sniderman, Allan D ^g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c CALAB Medical Laboratories   (Sweden)

^d NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Fatal myocardial infarction; Guidelines; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIAGNOSTIC VALUE; DIET RESTRICTION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 11244276995     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.254     Document Type: Article

References (44)

1. Adult Treatment Panel III. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Final Report. Circulation 2002; 106:3144-421.
2. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy [editorial]. Circulation 2002;106:2526-9.
3. De Backer G, Ambrosini E, Borch-Johansen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
4. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk factor cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
5. International Atherosclerosis Society. Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease. Executive Summary, 2003:1-23 (infoαthero.org).
6. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management and treatment of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 2003;169:921-4.
7. Swedish-Norwegian guidelines: behandling med lipid-sänkande läkemedel vid prevention av hjärt-kä rlsjukdom. Uppsala: Läkemedelsverket, 2003 (http://www.mpa.se, Information 2003 14/4).
8. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation 1996;94:273-8.
9. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-22.
10. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
11. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apoB and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-23.
12. Graziani MS, Zanolla L, Righetti G, Marchetti C, Mocarelli P, Marcovina S. Plasma apolipoprotein A-I and B in survivors of myocardial infarction and in a control group. Clin Chem 1998;44:134-40.
13. Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk - apolipoprotein A-I as an independent risk factor. Atherosclerosis 2001;155:165-7.
14. Luc G, Bard J-M, Ferrières J, Evans A, Amouyel P, Arveiler D, et al. Value of HDL-C, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary artery disease. The PRIME Study. Prospective epidemiological study of myocardial infarction. Arterioscler Thromb Vasc Biol 2002;22:1155-61.
15. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy: analysis of the evidence. Lancet 2003;361:777-80.
16. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994;40:586-92.
17. Otvos JD, Jeyarajah EJ, Cromvell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002;90:Suppl:22i-29i.
18. Otvos J. LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome: results from the Framingham Offspring Study. AHA 2003 Scientific Sessions Online, Orlando, FL, 2003.
19. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135:447-59.
20. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-79.
21. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-81.
22. Bachorik PS, Lovejoy KI, Carroll MD, Johnson CL. Apolipoprotein B and A-I distribution in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997;43:2364-78.
23. Jungner I, Marcovina S, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization - International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998;44:1641-9.
24. Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females. Int J Lab Res 1992;21:247-55.
25. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Yusuf S, Hawken S, Öunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarctioh in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
27. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl. Lower is better and physiologically normal. Expedited review. J Am Coll Cardiol 2004;43:2142-6.
28. Davidson MH. Emerging therapeutic strategies for the management of dyslipidemia in patients with metabolic syndrome. Am J Cardiol 2004;93:Suppl:3C-11C.
29. Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-161.
30. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weiss S, et al. Relation between baseline and ontreatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.
31. Barter PJ, Rye K. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 1996;7:82-7.
32. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant apoA-I Milano on coronary athersclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 2003;290:2322-4.
33. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-lowering therapy. J Intern Med 2004;255:188-205.
34. Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003;108:2312-6.
35. Sniderman AD. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol 2004;15:433-8.
36. Collins-Nakai RL, Daganais GR. The role of the cardiovascular specialist in the prevention of cardiovascular diseases - executive summary. Can J Cardiol 1999; Suppl G:7G-16G.
37. Leiter LA, Mahon J, Chye T. Macrovascular complications, dyslipidemia and hypertension. Can J Diabetes 2003;Suppl 2:S58-65.
38. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001;39:426-31.
39. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL; the twin Achilles heels of the Friedewald formula. Clin Biochem 2003;36:499-504.
40. Otvos JD. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular disease risk - clinical implications of lipoprotein quantification using NMR spectroscopy. J Lab Med 2002;26:544-50.
41. Miller WG, Waymack PP, Anderson PA, Ethridge SF, Jayne EC. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem 2002;48: 489-98.
42. Usui S, Kakuuchi H, Okamoto M, Mizukami Y, Okazaki M. Differential reactivity of two homogeneous LDL-cholesterol methods to LDL, and VLDL subfractions, as demonstrated by ultracentrifugation and HPLC. Clin Chem 2002;48:1946-54.
43. Steinmetz J, Cases E, Couderc R, Beucler I, Legrand A, Henney J. Reference values of apolipoprotein A-I and B. Contribution of international standardization. Ann Biol Clin 1997;55:451-4.
44. Mendis S, Yach D, Bengoa R, Narvaez D, Zhang X. Research gap in cardiovascular disease in developing countries. Lancet 2003;361:2246-7.